Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma Treatment Study
To compare event free survival in patients with newly diagnosed T-ALL and T-lymphoblastic lymphoma who are randomized to a modified ABFM (chemotherapy) backbone versus bortezomib plus the modified ABFM backbone.
In order to participate you must meet the following criteria:
- Are between 1 and 31 years of age.
- Have newly diagnosed T-lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma (T-LLy) stages II-IV.
This is a partial list of elgibility requirements.